Can I legally buy Cosyntropin in the EU?

No. Cosyntropin is not legally marketed in any EU member state. You cannot obtain it through pharmacies, hospitals' standard procurement, or online retailers. Importing it privately is illegal. If a hospital requires it for clinical use, they can request it through named-patient access procedures, but this is rare and restricted to documented medical need.

Is Cosyntropin banned in the EU?

No, it is not banned. It simply lacks marketing authorisation. There is a regulatory distinction: unauthorised medicines are not permitted to be sold, but they are not classified as prohibited substances. The practical outcome is the same — unavailability through normal channels — but the legal mechanism differs.

What should I use instead of Cosyntropin in the EU?

Tetracosactide ([Synacthen®](/compounds/tetracosactide)) is the licensed EU equivalent. Both are synthetic ACTH peptides used for ACTH stimulation testing. Synacthen® is EMA-authorised, widely available, and clinically equivalent. Most EU hospitals use tetracosactide as standard for diagnostic adrenal testing.

Why isn't Cosyntropin EMA-approved if it's safe and effective?

Cosyntropin was established as a diagnostic tool before the EMA's centralised procedure became standard. Manufacturers had no strong commercial incentive to pursue approval for a mature, niche diagnostic product. The cost and timeline of EMA submission (€5–15M, 18–36 months) is difficult to justify for modest market demand. Tetracosactide filled the market need, so approval was never pursued.

Can hospitals in the EU import Cosyntropin for research?

Yes, through named-patient or clinical trial authorisation pathways. A hospital can request unlicensed cosyntropin for specific research use if approved by ethics committees and national competent authorities. This requires documented justification and proper regulatory channels, but it is legally permissible for defined clinical or research purposes.

Cosyntropin Legal Status in the EU: Regulatory Overview

Cosyntropin is not authorised by the European Medicines Agency (EMA) and is therefore not legally marketed as a pharmaceutical product in EU member states. However, this doesn't mean it's entirely unavailable — member states can authorise its use under national procedures, and hospitals may access it through compassionate use or research pathways. Cosyntropin itself is a diagnostic peptide (synthetic ACTH), not a treatment. It's used exclusively in the ACTH stimulation test, the gold-standard diagnostic for adrenal insufficiency. Understanding its legal status requires separating diagnostic use from medicinal authorization.

Regulatory Status: Not EMA-Authorised

Cosyntropin does not hold a centralised marketing authorisation from the European Medicines Agency. This is the key fact that shapes its legal availability across the EU.

The EMA operates a centralised procedure for pharmaceutical approvals — once approved centrally, a medicine is authorised in all EU member states simultaneously. Cosyntropin has never been granted this authorisation, meaning it cannot be legally supplied as a registered pharmaceutical product through standard channels (pharmacies, hospitals' normal procurement systems) in any EU member state.

This is distinct from the United States, where Cosyntropin (marketed as Cortrosyn) has held FDA approval since the 1970s as a diagnostic agent. The divergence reflects different regulatory timelines and market priorities — EMA approval for diagnostic peptides has historically been less streamlined than in the US.

National Authorisation Pathways

While centralised EMA approval is the most common route, EU member states retain the ability to authorise medicines through national procedures under Article 10 of Directive 2001/83/EC. Some member states may have granted national marketing authorisations for cosyntropin, though this is uncommon for diagnostics.

Key distinction: even without an EMA authorisation, a medicine can be legally supplied in an EU member state if that country's national regulatory authority (such as the UK's MHRA, Germany's BfArM, or France's ANSM) has granted its own approval. However, availability varies significantly by country, and cosyntropin is rarely encountered through standard pharmacy or hospital procurement in practice.

Member states include Germany, France, Spain, Italy, Poland, Netherlands, Belgium, Austria, and others — regulatory approvals are not harmonised across all of them for unlicensed products.

Hospital and Research Access

In clinical practice, cosyntropin access in the EU typically occurs through two mechanisms:

1. Hospital Named-Patient Use (Compassionate Access) Hospitals can request unlicensed medicines for specific patients when no licensed alternative exists. This requires the prescribing doctor to justify medical need, and the hospital's pharmacy to source the product. The process is governed by national regulations and ethics committees. This is the most realistic pathway for diagnostic use in EU hospitals that regularly perform ACTH stimulation testing.

2. Clinical Trials Cosyntropin may be supplied to research centres conducting diagnostic validation studies under clinical trial authorisation. This requires approval from national competent authorities and ethics committees.

Regulatory History and Why EMA Approval Never Occurred

Cosyntropin is a mature diagnostic agent with decades of clinical use. The absence of EMA authorisation reflects market economics and historical timing rather than safety or efficacy concerns.

When the EMA's centralised procedure became the standard in the 1990s, cosyntropin was already established in the US and select European countries under national arrangements. Pharmaceutical manufacturers had limited commercial incentive to pursue centralised EMA approval for a diagnostic tool with stable, modest demand. The cost and timeline of a new EMA submission — typically €5–15 million and 18–36 months — is difficult to justify for a niche diagnostic product.

Additionally, diagnostic peptides were not a regulatory priority for the EMA during the 2000s–2010s, when the agency's focus was on innovative therapeutics for major diseases. Cosyntropin fell into a regulatory gap: too established to require approval, but never formally authorised centrally.

Enforcement and Import Restrictions

EU member states enforce pharmaceutical regulations through their national competent authorities. Unauthorised medicines — including cosyntropin — cannot be legally imported, manufactured, or distributed for commercial sale.

However, enforcement focuses on large-scale trafficking and non-compliant manufacturers. A hospital's one-off import of cosyntropin for diagnostic use under named-patient procedures is unlikely to trigger enforcement action, particularly if documented through proper channels.

Importing cosyntropin without a prescription or intended clinical use is illegal and would be intercepted by customs or pharmaceutical enforcement authorities.

Comparison to Licensed Alternatives

In diagnostic practice, some EU centres use tetracosactide (Synacthen®), which is EMA-authorised and widely available. Tetracosactide is functionally equivalent to cosyntropin — both are synthetic ACTH analogues that stimulate cortisol release. Synacthen® is the licensed equivalent in the EU and is the standard diagnostic agent in most European countries.

The clinical difference is minimal: both peptides trigger the same adrenal response. Synacthen® is slightly longer-acting due to zinc suspension formulation in some presentations. For hospitals, using a licensed alternative like tetracosactide eliminates regulatory friction.

What This Means for Patients and Healthcare Providers

For Patients: If your doctor wants to perform an ACTH stimulation test in the EU, they will likely use tetracosactide (Synacthen®) instead of cosyntropin. Both tests provide equivalent diagnostic information. You will not encounter cosyntropin in routine clinical care. Attempting to import cosyntropin privately is illegal and carries customs risk.

For Healthcare Providers: If you need cosyntropin specifically (for instance, to match protocols with international collaborators or historical data), you can request it through named-patient import procedures via your hospital pharmacy and national competent authority. This requires documented clinical justification and is appropriate for research settings. Standard procurement should use tetracosactide, which carries no regulatory ambiguity.

Regulatory Classification: Approved vs. Unauthorised

Cosyntropin's classification as "approved" in regulatory databases refers to its FDA status in the United States. In the EU, it is more accurately described as unlicensed but not prohibited. It is not a banned substance; it is simply not authorised for marketing. This is a critical distinction.

Approved compounds like tetracosactide have undergone formal EMA review and are subject to ongoing pharmacovigilance. Cosyntropin, as an unauthorised medicinal product in the EU, does not benefit from this oversight — nor does it incur the compliance burden of licensed status. For diagnostic use, this distinction is less critical than for therapeutics, since diagnostic agents have lower inherent safety risk.

Cross-Border Prescribing and Mutual Recognition

Under certain conditions, patients may have prescriptions filled in one EU country and the medicine dispensed in another (cross-border prescribing under Directive 2011/24/EU). However, this applies only to licensed medicines. Cosyntropin cannot be legally dispensed across borders in the EU because it has no marketing authorisation in any member state.

Future Regulatory Pathway

There is no active regulatory programme to obtain EMA authorisation for cosyntropin. The diagnostic peptide market is small, and tetracosactide already fulfils clinical need. Any future approval would require a manufacturer to invest in a new submission, which is economically unlikely.

If you encounter cosyntropin-specific clinical evidence (e.g., published studies showing superiority over tetracosactide for a particular diagnostic scenario), discussion with regulatory authorities about expedited pathways is theoretically possible but not currently active.

Cosyntropin's Legal Status in the European Union